Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page


My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1981 1
1996 1
1997 1
2000 3
2001 1
2002 2
2003 1
2005 1
2008 2
2009 2
2010 1
2011 2
2012 2
2013 1
2014 2
2015 1
2016 5
2017 3
2018 4
2019 5
2020 3
2021 4
2022 4
2023 6
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

58 results

Results by year

Filters applied: . Clear all
Page 1
Antibody-drug conjugates: in search of partners of choice.
Fuentes-Antrás J, Genta S, Vijenthira A, Siu LL. Fuentes-Antrás J, et al. Among authors: genta s. Trends Cancer. 2023 Apr;9(4):339-354. doi: 10.1016/j.trecan.2023.01.003. Epub 2023 Feb 4. Trends Cancer. 2023. PMID: 36746689 Free article. Review.
PARP Inhibitors in Ovarian Cancer.
Mittica G, Ghisoni E, Giannone G, Genta S, Aglietta M, Sapino A, Valabrega G. Mittica G, et al. Among authors: genta s. Recent Pat Anticancer Drug Discov. 2018;13(4):392-410. doi: 10.2174/1574892813666180305165256. Recent Pat Anticancer Drug Discov. 2018. PMID: 29512470 Free article. Review.
Phase 1 Study of JNJ-64619178, a Protein Arginine Methyltransferase 5 Inhibitor, in Advanced Solid Tumors.
Vieito M, Moreno V, Spreafico A, Brana I, Wang JS, Preis M, Hernández T, Genta S, Hansen AR, Doger B, Galvao V, Lenox L, Brown RJ, Kalota A, Mehta J, Pastore F, Patel B, Mistry P, Gu J, Lauring J, Patel MR. Vieito M, et al. Among authors: genta s. Clin Cancer Res. 2023 Sep 15;29(18):3592-3602. doi: 10.1158/1078-0432.CCR-23-0092. Clin Cancer Res. 2023. PMID: 37491846 Clinical Trial.
Adoptive immunotherapy against ovarian cancer.
Mittica G, Capellero S, Genta S, Cagnazzo C, Aglietta M, Sangiolo D, Valabrega G. Mittica G, et al. Among authors: genta s. J Ovarian Res. 2016 May 17;9(1):30. doi: 10.1186/s13048-016-0236-9. J Ovarian Res. 2016. PMID: 27188274 Free PMC article. Review.
Autoimmune PaneLs as PrEdictors of Toxicity in Patients TReated with Immune Checkpoint InhibiTors (ALERT).
Genta S, Lajkosz K, Yee NR, Spiliopoulou P, Heirali A, Hansen AR, Siu LL, Saibil S, Stayner LA, Yanekina M, Sauder MB, Keshavarzi S, Salawu A, Vornicova O, Butler MO, Bedard PL, Razak ARA, Rottapel R, Chruscinski A, Coburn B, Spreafico A. Genta S, et al. J Exp Clin Cancer Res. 2023 Oct 21;42(1):276. doi: 10.1186/s13046-023-02851-6. J Exp Clin Cancer Res. 2023. PMID: 37865776 Free PMC article.
Veliparib: a new therapeutic option in ovarian cancer?
Ghisoni E, Giannone G, Tuninetti V, Genta S, Scotto G, Aglietta M, Sangiolo D, Mittica G, Valabrega G. Ghisoni E, et al. Among authors: genta s. Future Oncol. 2019 Jun;15(17):1975-1987. doi: 10.2217/fon-2018-0883. Epub 2019 May 10. Future Oncol. 2019. PMID: 31074636 Review.
Role of Cyclin-Dependent Kinase Inhibitors in Endometrial Cancer.
Giannone G, Tuninetti V, Ghisoni E, Genta S, Scotto G, Mittica G, Valabrega G. Giannone G, et al. Among authors: genta s. Int J Mol Sci. 2019 May 12;20(9):2353. doi: 10.3390/ijms20092353. Int J Mol Sci. 2019. PMID: 31083638 Free PMC article. Review.
58 results